Relevant bibliographies by topics / Cosentyx

Contents

  1. Journal articles
  2. Book chapters

Academic literature on the topic 'Cosentyx'

Author: Grafiati
Published: 3 June 2025
Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cosentyx.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cosentyx"

1

Chebysheva, S. N., E. S. Zholobova, N. A. Geppe, et al. "Efficacy and safety of secukinumab (Cosentyx) in patients with juvenile psoriatic arthritis." Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 70, no. 1 (2025): 75–81. https://doi.org/10.21508/1027-4065-2025-70-1-75-81.

Full text
Abstract:
Psoriatic arthritis is a chronic inflammatory disease of the peripheral joints, spinal joints and entheses, occurring in 10–25% of patients with psoriasis. Juvenile psoriatic arthritis is classified as a subtype of juvenile idiopathic arthritis. Treatment of juvenile psoriatic arthritis is challenging. One of the main difficulties is that the drugs used in adult patients have restrictions for use in pediatric practice, which limits the available therapeutic options. There are few studies assessing the effectiveness and safety of secakinumab therapy in pediatric practice.Objective. To evaluate
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, A. S. W., N. J. Levell, S. N. Shah, K. Gaffney, and M. A. W. Tremelling. "Severe colitis complicating secukinumab (Cosentyx ® ) therapy." Clinical and Experimental Dermatology 45, no. 3 (2020): 344–45. http://dx.doi.org/10.1111/ced.14149.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Di Giuseppe, Luis A., Gabriela Buela, María Laura Galimberti, Karina Elena Álvarez, Leonardo G. Garfi, and Sergio A. Terrasa. "Experiencia de un contrato de riesgo compartido basado en resultados para el tratamiento de psoriasis en placa con secukinumab (Cosentyx)." Economía de la Salud 17 (July 2022): 57–64. http://dx.doi.org/10.61679/1703057064.

Full text
Abstract:
Objetivo: Este trabajo busca describir el proceso y analizar los resultados a las 16 semanas de la implementación de un contrato de riesgo compartido basado en resultados (CRCBR) para el tratamiento con secukinumab (Cosentyx) en pacientes con psoriasis en placa. Materiales y métodos: En 2016, el Área de Gestión de Fármacos e Insumos del Plan de Salud (PS) del Hospital Italiano de Buenos Aires desarrolló un CRCBR para la utilización de secukinumab en pacientes adultos con psoriasis en placa moderada a severa que nunca hubieran recibido tratamientos biológicos. Se acordó con Novartis Argentina S
APA, Harvard, Vancouver, ISO, and other styles
4

Lukoviek, Vania, María Arteaga Henríquez, José María Ramírez Conchas, Judit Algarra Sahuquillo, Marcella Markthaler, and Marta García Bustinduy. "18292 Fibrosis-4 index in psoriasis patients treated with methotrexate before cosentyx: A descriptive study." Journal of the American Academy of Dermatology 83, no. 6 (2020): AB209. http://dx.doi.org/10.1016/j.jaad.2020.06.924.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sun, Hanxi, Jason Plawinski, Sajanth Subramaniam, et al. "A deep learning approach to private data sharing of medical images using conditional generative adversarial networks (GANs)." PLOS ONE 18, no. 7 (2023): e0280316. http://dx.doi.org/10.1371/journal.pone.0280316.

Full text
Abstract:
Clinical data sharing can facilitate data-driven scientific research, allowing a broader range of questions to be addressed and thereby leading to greater understanding and innovation. However, sharing biomedical data can put sensitive personal information at risk. This is usually addressed by data anonymization, which is a slow and expensive process. An alternative to anonymization is construction of a synthetic dataset that behaves similar to the real clinical data but preserves patient privacy. As part of a collaboration between Novartis and the Oxford Big Data Institute, a synthetic datase
APA, Harvard, Vancouver, ISO, and other styles
6

Darch, K. M., T. L. Holland, and L. J. Spelman. "Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23." Case Reports in Medicine 2020 (July 24, 2020): 1–6. http://dx.doi.org/10.1155/2020/9404505.

Full text
Abstract:
Chronic plaque psoriasis and psoriatic arthritis are common autoimmune inflammatory conditions, often existing as comorbidities that have a significant impact on a patient’s quality of life. The availability of a range of novel, targeted therapies for their treatment, most notably the availability of biologic agents, has revolutionised management of these conditions and allowed for significant improvements in patient outcomes. Secukinumab (Cosentyx), a fully-human monoclonal antibody that acts by selectively binding to and neutralising the proinflammatory cytokine IL-17A, is used widely for th
APA, Harvard, Vancouver, ISO, and other styles
7

Sluzevich, Jason C., Meera H. Patel, Thais P. Pincelli, Caitlin M. Brumfiel, Mark R. Pittelkow, and Aaron Mangold. "25240 Cosentyx (secukinumab) for the treatment of adult onset pityriasis rubra pilaris: A single arm, open-label exploratory study." Journal of the American Academy of Dermatology 85, no. 3 (2021): AB55. http://dx.doi.org/10.1016/j.jaad.2021.06.244.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sears, A. V., C. Szlumper, K. W. Liu, C. H. Smith, J. N. W. N. Barker, and A. E. Pink. "Clinical outcomes in patients on secukinumab (Cosentyx® ) within a specialist psoriasis clinic: a single centre, retrospective cohort study." Journal of the European Academy of Dermatology and Venereology 33, no. 2 (2018): e89-e91. http://dx.doi.org/10.1111/jdv.15245.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yao, Feng, Chenguang Wang, Jie Ding, et al. "A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects." Drug Design, Development and Therapy Volume 18 (August 2024): 3891–901. http://dx.doi.org/10.2147/dddt.s470619.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Eviatar, T., D. Zisman, M. Lidar, T. Reitblat, A. Balbir-Gurman, and O. Elkayam. "FRI0337 REAL WORLD SECUKINUMAB DRUG-SURVIVAL IN PSORIATIC ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 761.1–762. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3729.

Full text
Abstract:
Background:Secukinumab (Cosentyx) is a human IgG1 monoclonal antibody that selectively binds to and neutralizes IL-17A. Several prospective randomized control trials have demonstrated the efficacy and safety of secukinumab in PsA, but there is a paucity of real life data in the PsA population.Objectives:To prospectively study secukinumab’s safety, efficacy, and tolerability in the cohort of PsA patients from the Israeli registry of inflammatory diseases.Methods:PsA patients fulfilling the CASPAR criteria from the Israeli registry of inflammatory diseases were included in the analysis, from 201
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cosentyx"

1

Asim, Muhammad. "IL-17 and IL-23 inhibitors and targeted synthetic DMARDs." In Ankylosing Spondylitis and Axial Spondyloarthritis, 2nd ed. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/oso/9780198864158.003.0020.

Full text
Abstract:
Abstract Many novel drugs are revolutionizing the care of people with SpA, especially for those who fail to respond to TNFi. IL-17 inhibitors secukinumab (Cosentyx®) and ixekizumab (Taltz®) are very effective for treating people with AS/axSpA, psoriasis, and PsA, but they are not effective for IBD. They slow down disease progression beginning a couple of years after treatment initiation that is initiated in early stages of the disease. IL-23 inhibitors ustekinumab (Stelara®), guselkumab (Tremfya®) and risankizumab (Skyrizi®) are approved for psoriasis and PsA. They have unprecedented efficacy
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cosentyx' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography